NOT KNOWN DETAILS ABOUT HEMGENIX

Amount of qualified individuals: CDEC discussed the uncertainty in the amount of people with moderately critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some patients who're labeled as acquiring mild or moderate sickness may have a serious bleeding phenotype, which